SEC Form 4 · accession 0001104659-16-140127

Amphastar Pharmaceuticals, Inc. · AMPH

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Aug 12, 2016

Accepted (ET)

Aug 16, 2016 · 8:31 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001297184

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Aug 12, 2016	M	10,381	$15.23	A	42,792	D
Common Stock	Aug 12, 2016	M	20,594	$14.23	A	63,386	D
Common Stock^F1	Aug 12, 2016	S	30,975	$18.1157	D	32,411	D
Common Stock	Aug 15, 2016	M	17,400	$14.23	A	49,811	D
Common Stock^F2	Aug 15, 2016	S	17,400	$18.2168	D	32,411	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F3	$15.23	Aug 12, 2016	M	10,381	D	—	Oct 3, 2016	Common Stock	10,381	0	D
Stock Option (right to buy)^F3	$14.23	Aug 12, 2016	M	20,594	D	—	Dec 10, 2016	Common Stock	20,594	17,400	D
Stock Option (right to buy)^F3	$14.23	Aug 15, 2016	M	17,400	D	—	Dec 10, 2016	Common Stock	17,400	0	D

F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4.
F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.39, inclusive.
F3Shares subject to the option are fully vested and immediately exercisable.